Ehesan U. Sharif
0000-0002-2605-6745
Publication & Citation Trends
Publications
0 total
Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors.
Cited by 3
Semantic Scholar
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy.
Cited by 0
Semantic Scholar
Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801
Cited by 0
Semantic Scholar
Abstract PR001: Discovery of Etrumadenant, a first-in-class dual A2a and A2b adenosine receptor antagonist for cancer immunotherapy
Cited by 1
Semantic Scholar
854 HPK1 inhibition relieves suppression downstream of TCR activation to drive enhanced cytokine production and antigen-specific killing, an effect that is further enhanced by immune checkpoint blockade OA
Cited by 0
Semantic Scholar
Abstract 1367: HPK1 inhibition enhances T cell activation and relieves the immunosuppressive phenotype of inhibitory signals found in the tumor microenvironment
Cited by 1
Semantic Scholar
Development of a Robust and Scalable Synthetic Route for a Potent and Selective Isoindolinone PI3Kγ Inhibitor
Cited by 7
Semantic Scholar
Research Topics
Adenosine and Purinergic Signaling
(9)
Microbial Natural Products and Biosynthesis
(7)
Carbohydrate Chemistry and Synthesis
(7)
Nanoplatforms for cancer theranostics
(6)
Synthetic Organic Chemistry Methods
(6)
Affiliations
Northeastern University
Stanford Medicine
Pulse Biosciences (United States)
Qatar University
Universidad del Noreste